Loading...
MTAA
DIA
Market cap3.75bUSD
Dec 05, Last price  
62.24EUR
1D
3.60%
1Q
-24.41%
Jan 2017
10.65%
IPO
420.40%
Name

DiaSorin SpA

Chart & Performance

D1W1MN
MTAA:DIA chart
P/E
17.71
P/S
2.81
EPS
3.52
Div Yield, %
1.91%
Shrs. gr., 5y
0.34%
Rev. gr., 5y
10.90%
Revenues
1.19b
+3.20%
165,339,000179,756,000202,324,000244,612,000304,129,000404,547,000440,003,000433,763,000434,849,000443,770,000499,181,000569,312,000637,487,000669,197,000706,319,000881,305,0001,237,654,0001,361,138,0001,148,210,0001,185,000,000
Net income
188m
+17.68%
4,678,00022,294,00025,219,00037,459,00070,047,00090,418,00099,607,00087,396,00083,028,00084,074,000100,420,000112,383,000139,878,000158,128,000175,735,000247,871,000310,968,000240,907,000159,849,000188,105,000
CFO
359m
+15.12%
21,132,00033,976,00030,348,00047,779,00064,219,00095,791,000108,578,000110,582,000107,717,000119,847,000138,449,000165,597,000167,440,000209,879,000232,670,000304,562,000400,664,000389,341,000311,663,000358,782,000
Dividend
May 20, 20241.15 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
IPO date
Jul 19, 2007
Employees
3,278
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT